CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...

The drug is expected to be formally approved by the European Commission this year. View on euronews ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

In a major breakthrough in the fight against HIV, the European Medicines Agency (EMA) has recommended the approval of lenacapavir, a twice-yearly injectable drug developed by Gilead Sciences and ...

"In our opinion, it's the best tool yet in helping end the HIV epidemic for everyone, everywhere." Others agree. In 2024, Science hailed lenacapavir as its "Breakthrough of the Year" in 2024. The ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

DAP Health is presenting “Next Gen Care: Innovations in HIV Prevention,” an event that will highlight cutting-edge care and ...

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

A pharmacist holds a vial of lenacapavir, the injectable drug that prevents HIV infection. On June 18, the FDA approved the drug for use in the U.S.

"That looks like a lot of drug, but if there are 1.3 million new HIV infections every year, and you need to treat between 40-50 people with a preventative drug to prevent one infection, then 2 ...